412 related articles for article (PubMed ID: 33745080)
1. Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
Sternschuss M; Yerushalmi R; Saleh RR; Amir E; Goldvaser H
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3369-3379. PubMed ID: 33745080
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis.
Xin Y; Shen G; Zheng Y; Guan Y; Huo X; Li J; Ren D; Zhao F; Liu Z; Li Z; Zhao J
BMC Cancer; 2021 Nov; 21(1):1261. PubMed ID: 34814874
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
Zhang M; Song J; Yang H; Jin F; Zheng A
Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
Liang X; Chen X; Li H; Li Y
Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
[TBL] [Abstract][Full Text] [Related]
7. Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis.
Villacampa G; Tolosa P; Salvador F; Sánchez-Bayona R; Villanueva L; Dienstmann R; Ciruelos E; Pascual T
Cancer Treat Rev; 2022 Mar; 104():102352. PubMed ID: 35144055
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis.
Yu Y; Jin X; Zhu X; Xu Y; Si W; Zhao J
Front Immunol; 2023; 14():1206689. PubMed ID: 37377959
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors as neoadjuvant therapy in early triple-negative breast cancer: A systematic review and meta-analysis.
Mittal N; Singh S; Mittal R; Kaushal J; Kaushal V
J Cancer Res Ther; 2022; 18(6):1754-1765. PubMed ID: 36412440
[TBL] [Abstract][Full Text] [Related]
10. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
[TBL] [Abstract][Full Text] [Related]
11. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
Poggio F; Bruzzone M; Ceppi M; Pondé NF; La Valle G; Del Mastro L; de Azambuja E; Lambertini M
Ann Oncol; 2018 Jul; 29(7):1497-1508. PubMed ID: 29873695
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of PD-L1 expression to the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer: A systematic review and meta-analysis.
Qi Y; Yan X; Wang C; Cao H; Liu G
Front Pharmacol; 2022; 13():1004821. PubMed ID: 36532783
[No Abstract] [Full Text] [Related]
13. Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis.
Rizzo A; Cusmai A; Massafra R; Bove S; Comes MC; Fanizzi A; Rinaldi L; Acquafredda S; Gadaleta-Caldarola G; Oreste D; Zito A; Giotta F; Lorusso V; Palmiotti G
Cells; 2022 Jun; 11(12):. PubMed ID: 35740985
[TBL] [Abstract][Full Text] [Related]
14. Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety.
Sharmni Vishnu K; Win TT; Aye SN; Basavaraj AK
BMC Cancer; 2022 Nov; 22(1):1139. PubMed ID: 36335316
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Immune Checkpoint Inhibitors in Triple-negative Breast Cancer: A Study Based on 41 Cohorts Incorporating 6558 Participants.
Wu Q; Wu C; Xie X
J Immunother; 2023 Feb-Mar 01; 46(2):29-42. PubMed ID: 36378154
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
Li Y; Xing L; Li F; Liu H; Gan L; Yang D; Wang M; Yin X; Li H; Ren G
Front Oncol; 2021; 11():657634. PubMed ID: 34912699
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.
Cui W; Luo Q; Sun SL; Xu JL; Gu H
Recenti Prog Med; 2022 Dec; 113(12):722-732. PubMed ID: 36420848
[TBL] [Abstract][Full Text] [Related]
18. Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials.
Huo X; Shen G; Liu Z; Liang Y; Li J; Zhao F; Ren D; Zhao J
Crit Rev Oncol Hematol; 2021 Dec; 168():103530. PubMed ID: 34801695
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials.
Tarantino P; Gandini S; Trapani D; Criscitiello C; Curigliano G
Crit Rev Oncol Hematol; 2021 Mar; 159():103223. PubMed ID: 33482345
[TBL] [Abstract][Full Text] [Related]
20. Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: A systematic review and meta-analysis.
Gao X; Zhu Y; Wang P; Yu L; Ruan S; Shen M; Zhang K
Cancer Med; 2023 Dec; 12(24):21873-21884. PubMed ID: 38063264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
